AU2015335788B2 - Thiazolyl-containing compounds for treating proliferative diseases - Google Patents

Thiazolyl-containing compounds for treating proliferative diseases Download PDF

Info

Publication number
AU2015335788B2
AU2015335788B2 AU2015335788A AU2015335788A AU2015335788B2 AU 2015335788 B2 AU2015335788 B2 AU 2015335788B2 AU 2015335788 A AU2015335788 A AU 2015335788A AU 2015335788 A AU2015335788 A AU 2015335788A AU 2015335788 B2 AU2015335788 B2 AU 2015335788B2
Authority
AU
Australia
Prior art keywords
substituted
alkyl
unsubstituted
carbamate
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015335788A
Other languages
English (en)
Other versions
AU2015335788A1 (en
Inventor
Sara Jean Buhrlage
Hwan Geun Choi
Nathanael S. Gray
Steven P. Treon
Yuan Xiong
Guang Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2015335788A1 publication Critical patent/AU2015335788A1/en
Application granted granted Critical
Publication of AU2015335788B2 publication Critical patent/AU2015335788B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015335788A 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases Ceased AU2015335788B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462067178P 2014-10-22 2014-10-22
US62/067,178 2014-10-22
PCT/US2015/056899 WO2016065138A1 (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Publications (2)

Publication Number Publication Date
AU2015335788A1 AU2015335788A1 (en) 2017-05-04
AU2015335788B2 true AU2015335788B2 (en) 2020-07-30

Family

ID=55761545

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015335788A Ceased AU2015335788B2 (en) 2014-10-22 2015-10-22 Thiazolyl-containing compounds for treating proliferative diseases

Country Status (7)

Country Link
US (3) US10112957B2 (cg-RX-API-DMAC10.html)
EP (2) EP3715346B1 (cg-RX-API-DMAC10.html)
JP (1) JP6788583B2 (cg-RX-API-DMAC10.html)
AU (1) AU2015335788B2 (cg-RX-API-DMAC10.html)
CA (1) CA2965178C (cg-RX-API-DMAC10.html)
IL (1) IL251790B (cg-RX-API-DMAC10.html)
WO (1) WO2016065138A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CA2965178C (en) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
HUE054912T2 (hu) * 2016-07-14 2021-10-28 Lilly Co Eli Pirazolil-amino-benzimidazol-származékok mint JAK inhibitorok
PT3534899T (pt) * 2016-11-03 2022-07-07 Corvus Pharmaceuticals Inc Compostos e métodos de modulação da cinase de células t induzível por interleucina-2
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
CN109265455B (zh) * 2018-11-09 2020-08-18 新发药业有限公司 一种达沙替尼的制备方法
MX2022010391A (es) * 2020-02-26 2022-09-05 Daewoong Pharmaceutical Co Ltd Metodo de preparacion de derivados de amina heterociclica.
JP7691991B2 (ja) * 2020-03-06 2025-06-12 ナショナル・ヘルス・リサーチ・インスティテューツ ピリミジン化合物及びその薬学的使用
WO2024111626A1 (ja) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 新規チアゾール誘導体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
AU3653099A (en) 1998-04-17 1999-11-08 Parker Hughes Institute Btk inhibitors and methods for their identification and use
BR9912729A (pt) 1998-08-04 2001-05-02 Astrazeneca Ab Derivado de amida, processo para prepará-lo, e, uso do mesmo
ATE254105T1 (de) 1998-09-25 2003-11-15 Astrazeneca Ab Benzamid-derivate und ihre verwendung als cytokine inhibitoren
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
JP4896518B2 (ja) 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
TW200634003A (en) 2004-12-22 2006-10-01 Astrazeneca Ab Chemical compounds
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
US7375951B2 (en) * 2006-07-07 2008-05-20 Lutron Electronics Co., Inc. Load control device having a split enclosure
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP1957461B1 (en) 2005-11-14 2016-11-02 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
WO2007076474A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
US20090312396A1 (en) 2006-07-10 2009-12-17 Astrazeneca Ab Methods for cancer treatment using tak1 inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
TW200906825A (en) * 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
US7928140B2 (en) * 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
KR20100058660A (ko) 2007-10-23 2010-06-03 테바 파마슈티컬 인더스트리즈 리미티드 다사티닙 다형체 및 이의 제조 방법
WO2009076373A1 (en) 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
CA2723237A1 (en) 2008-05-06 2009-11-12 Peter A. Blomgren Substituted amides, method of making, and use as btk inhibitors
CA2735208A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
MX2012002591A (es) 2009-09-03 2012-04-02 Allergan Inc Compuestos como moduladores de tirosina cinasas.
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
AU2011328237A1 (en) 2010-11-09 2013-05-23 Cellzome Limited Pyridine compounds and aza analogues thereof as TYK2 inhibitors
EP2640366A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
LT2714677T (lt) 2011-05-23 2018-12-10 Merck Patent Gmbh Piridino ir pirazino dariniai
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014528957A (ja) 2011-10-03 2014-10-30 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 殺虫性化合物
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
TW201326171A (zh) 2011-11-03 2013-07-01 Genentech Inc 烷基化哌□化合物
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
CN103405429A (zh) 2013-08-22 2013-11-27 中国药科大学 一类vegfr-2抑制剂及其用途
WO2015069287A1 (en) 2013-11-08 2015-05-14 Allergan, Inc. Compounds as tyrosine kinase modulators
USRE50030E1 (en) 2013-12-13 2024-07-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CA2965178C (en) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081172A2 (en) * 2005-01-26 2006-08-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANK E. KWARCINSKI ET AL, "Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine", ACS CHEMICAL BIOLOGY, US, 2012, vol. 7, no. 11, pages 1910 - 1917 *

Also Published As

Publication number Publication date
AU2015335788A1 (en) 2017-05-04
JP6788583B2 (ja) 2020-11-25
US10112957B2 (en) 2018-10-30
US10464949B2 (en) 2019-11-05
US20190119301A1 (en) 2019-04-25
US20170233411A1 (en) 2017-08-17
CA2965178C (en) 2023-09-26
EP3209648B1 (en) 2020-03-11
EP3209648A4 (en) 2018-07-25
EP3715346B1 (en) 2024-01-03
EP3715346A1 (en) 2020-09-30
EP3209648A1 (en) 2017-08-30
IL251790B (en) 2019-08-29
IL251790A0 (en) 2017-06-29
WO2016065138A1 (en) 2016-04-28
JP2017537886A (ja) 2017-12-21
US10844077B2 (en) 2020-11-24
CA2965178A1 (en) 2016-04-28
US20200165267A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
US12509455B2 (en) Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof
US10844077B2 (en) Thiazolyl-containing compounds for treating proliferative diseases
AU2016283105B2 (en) 4,6-pyrimidinylene derivatives and uses thereof
JP6854762B2 (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
US10342798B2 (en) Fused bicyclic pyrimidine derivatives and uses thereof
US12522583B2 (en) Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
AU2020357983B2 (en) Tricyclic kinase inhibitors and uses thereof
WO2020140098A1 (en) Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA2988330C (en) 4,6-pyrimidinylene derivatives and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired